[go: up one dir, main page]

WO2006026097A3 - Pegylation of antibodies against hiv - Google Patents

Pegylation of antibodies against hiv Download PDF

Info

Publication number
WO2006026097A3
WO2006026097A3 PCT/US2005/028414 US2005028414W WO2006026097A3 WO 2006026097 A3 WO2006026097 A3 WO 2006026097A3 US 2005028414 W US2005028414 W US 2005028414W WO 2006026097 A3 WO2006026097 A3 WO 2006026097A3
Authority
WO
WIPO (PCT)
Prior art keywords
pegylation
hiv
relates
antibodies against
against hiv
Prior art date
Application number
PCT/US2005/028414
Other languages
French (fr)
Other versions
WO2006026097A2 (en
Inventor
Vijay Ramakrishnan
Original Assignee
Vijay Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vijay Ramakrishnan filed Critical Vijay Ramakrishnan
Publication of WO2006026097A2 publication Critical patent/WO2006026097A2/en
Publication of WO2006026097A3 publication Critical patent/WO2006026097A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the pegylation of therapeutic antibodies to treat HIV infections. More specifically, the invention relates to site-specific pegylation of X5 scFv antibody fragments at specifically defined amino acid residue(s) that is optionally engineered away from the antigen binding sites. The pegylated-MAb derivatives show substantially improved pharmacokinetic and pharmacodynamic properties, and they are broadly-neutralizing against several HIV clinical isolates by selectively binding to a highly conserved CD4-inducible epitope of HIV gp120.
PCT/US2005/028414 2004-08-25 2005-08-09 Pegylation of antibodies against hiv WO2006026097A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60399304P 2004-08-25 2004-08-25
US60/603,993 2004-08-25

Publications (2)

Publication Number Publication Date
WO2006026097A2 WO2006026097A2 (en) 2006-03-09
WO2006026097A3 true WO2006026097A3 (en) 2006-08-10

Family

ID=36000514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028414 WO2006026097A2 (en) 2004-08-25 2005-08-09 Pegylation of antibodies against hiv

Country Status (1)

Country Link
WO (1) WO2006026097A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518723A (en) * 1993-05-07 1996-05-21 Akzo Nobel N.V. HIV immunogenic complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518723A (en) * 1993-05-07 1996-05-21 Akzo Nobel N.V. HIV immunogenic complexes
US6030772A (en) * 1993-05-07 2000-02-29 Akzo Nobel N.V. Neutralizing antibodies against HIV infection
US6465172B1 (en) * 1993-05-07 2002-10-15 BIOMéRIEUX, INC. HIV immunogenic complexes comprising GP120 covalently bound to CD4 or concanavalin A

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAPMAN A.P.: "PEGylated antibodies and antibody fragments for improved therapy: a review", ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 531 - 545, XP001199533 *
MOULARD M. ET AL.: "Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes", PROCEEDINGS OF THE AMERICAN ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 10, 14 May 2002 (2002-05-14), pages 6913 - 6918, XP002968346 *

Also Published As

Publication number Publication date
WO2006026097A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2006023420A3 (en) Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2008031577A8 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2008063771A3 (en) Anti-cd20 antibodies and methods of use
WO2005035584A8 (en) Fully human antibodies against human 4-1bb (cd137)
JP2010515717A5 (en)
JP2011527902A5 (en)
GEP20074222B (en) Antibodies to cd40
WO2003034903A3 (en) Psma antibodies and protein multimers
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2004084798A3 (en) Antigen-presenting complex-binding compositions and uses thereof
NZ724971A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
UA92505C2 (en) Anti-cd3 antibody formulations
EP2221317A3 (en) PEGylated single domain antibodies (dAb)
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2006050280A3 (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2007109747A3 (en) Methods and compositions for antagonism of rage
WO2006036291A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007001457A3 (en) Antibodies operably linked to selected chemoattractants
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2011064257A3 (en) Monospecific polypeptide reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69 1 EPC

122 Ep: pct application non-entry in european phase

Ref document number: 05784258

Country of ref document: EP

Kind code of ref document: A2